nach oben

Erschienen in:

28.05.2018 | Clinical trial

Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08)

verfasst von: Noorie Choi, Kyubo Kim, Kyung Hwan Shin, Yumi Kim, Hyeong-Gon Moon, Won Park, Doo Ho Choi, Su Ssan Kim, Seung Do Ahn, Tae Hyun Kim, Mison Chun, Yong Bae Kim, Suzy Kim, Byung Ock Choi, Jin Hee Kim

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify risk factors for local recurrence (LR) and investigate roles of adjuvant local therapy for malignant and borderline phyllodes tumors of the breast.

Methods

From 1981 to 2014, 362 patients with malignant (n = 235) and borderline (n = 127) phyllodes tumors were treated by breast-conserving surgery (BCS) or total mastectomy (TM) at 10 centers. Thirty-one patients received adjuvant radiation therapy (RT), and those who received adjuvant chemotherapy were excluded from the study.

Results

Median follow-up was 5 years. LR developed in 60 (16.6%) patients. Regional recurrence occurred in 2 (0.6%) patients and distant metastasis (DM) developed in 19 (5.2%) patients. Patients receiving BCS (p = 0.025) and those not undergoing adjuvant RT (p = 0.041) showed higher LR rates. For malignant subtypes, local control (LC) rates at 5 years for BCS alone, BCS with adjuvant RT, TM alone, and TM with adjuvant RT were 80.7, 93.3, 92.4, and 100%, respectively (p = 0.033). Multivariate analyses revealed BCS alone, tumor size ≥ 5 cm, and positive margins as independent risk factors for LR. Margin-positive BCS alone showed poorest LC regardless of tumor size (62.5%, p = 0.007). For margin-negative BCS alone, 5-year LC rates for tumors ≥ 5 cm versus those < 5 cm were 71.8% versus 89.5% (p = 0.012). For borderline subtypes, only positive margins (p = 0.044) independently increased the risk of LR. DM developed exclusively in malignant subtypes and a prior LR event increased the risk of DM by sixfold (HR 6.2, 95% CI 1.6–16.1, p = 0.001).

Conclusions

Malignant and borderline phyllodes tumors with positive margins after surgery have high LR rates. After treatment by margin-negative BCS alone, patients with large malignant phyllodes tumors ≥ 5 cm also have heightened risk of LR. Thus, such patients should be considered for additional local therapy.

Rowell MDPR, Hsiu JG, Barranco SC (1993) Phyllodes tumors. Am J Surg 165(3):376–379PubMedCrossRef

Reinfuss M, Mituś J, Duda K, Stelmach A, Ryś J, Smolak K (1996) The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77(5):910–916PubMedCrossRef

Strode M, Khoury T, Mangieri C, Takabe K (2017) Update on the diagnosis and management of malignant phyllodes tumors of the breast. Breast 33:91–96PubMedCrossRef

World Health Organization (1981) Histologic typing of breast tumors, 2nd edn. WHO, Geneva

Lakhani SREI., Schnitt SJ, Tan PH, van de Vijver MJ (2012) World Health Organization classification of tumours, 4th edn. IARC, Lyon

Zhou ZR, Wang CC, Yang ZZ, Yu XL, Guo XM (2016) Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence. J Thorac Dis 8(11):3361–3368PubMedPubMedCentralCrossRef

Zhang Y, Kleer CG (2016) Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 140(7):665–671PubMedCrossRef

Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS et al (2004) Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol 11(11):1011–1017PubMedCrossRef

National Comprehensive Cancer Network. Breast Cancer (Version 2. 2016). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 Dec 2017

10.

Barth RJ Jr, Wells WA, Mitchell SE, Cole BF (2009) A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 16(8):2288–2294PubMedPubMedCentralCrossRef

11.

Pezner RD, Schultheiss TE, Paz IB (2008) Malignant phyllodes tumor of the breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys 71(3):710–713PubMedCrossRef

12.

Tremblay-LeMay R, Hogue JC, Provencher L, Poirier B, Poirier E, Laberge S et al (2017) How wide should margins be for phyllodes tumors of the breast? Breast J 23(3):315–322PubMedCrossRef

13.

Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S et al (2013) Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 88(2):427–436PubMedCrossRef

14.

Tan PH, Jayabaskar T, Chuah KL, Lee HY, Tan Y, Hilmy M et al (2005) Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol 123(4):529–540PubMedCrossRef

15.

Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magne N, Malard Y (2008) et a. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 70(2):492–500PubMedCrossRef

16.

Co M, Chen C, Tsang JY, Tse G, Kwong A (2017) Mammary phyllodes tumour: a 15-year multicentre clinical review. J Clin Pathol. https://doi.org/10.1136/jclinpath-2017-204827 PubMedCrossRef

17.

Borhani-Khomani K, Talman ML, Kroman N, Tvedskov TF (2016) Risk of local recurrence of benign and borderline phyllodes tumors: a Danish population-based retrospective study. Ann Surg Oncol 23(5):1543–1548PubMedCrossRef

18.

Jang JH, Choi MY, Lee SK, Kim S, Kim J, Lee J et al (2012) Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol 19(8):2612–2617PubMedCrossRef

19.

Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ (2014) Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol 21(10):3304–3309PubMedCrossRef

20.

Koh VCY, Thike AA, Nasir NDM, Yip GWC, Bay BH, Tan PH (2016) Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast. Virchows Arch 472(4):615–621CrossRef

21.

Zhou ZR, Wang CC, Sun XJ, Yang ZZ, Chen XX, Shao ZM et al (2018) Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. Cancer Med 7(4):1030–1042PubMedPubMedCentralCrossRef

22.

Rodrigues MF, Truong PT, McKevitt EC, Weir LM, Knowling MA, Wai ES (2018) Phyllodes tumors of the breast: the British Columbia Cancer Agency experience. Cancer Radiother 22(2):112–119PubMedCrossRef

23.

Yom CK, Han W, Kim SW, Park SY, Park IA, Noh DY (2015) Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol 22(9):2912–2918PubMedCrossRef

24.

Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA (2014) Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998–2009. Ann Surg Oncol 21(4):1222–1230PubMedCrossRef

25.

Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK (2006) Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 107(9):2127–2233PubMedCrossRef

26.

Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GP (2001) Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 27(8):723–730PubMedCrossRef

27.

Hajdu SI, Espinosa MH, Robbins GF (1976) Recurrent cystosarcoma phyllodes: a clinicopathologic study of 32 cases. Cancer 38(3):1402–1406PubMedCrossRef

28.

Faraci RP, Schour L (1974) Radical treatment of recurrent cystosarcoma phyllodes. Ann Surg 180(5):796–798PubMedPubMedCentralCrossRef

29.

Adesoye T, Neuman HB, Wilke LG, Schumacher JR, Steiman J, Greenberg CC (2016) Current trends in the management of phyllodes tumors of the breast. Ann Surg Oncol 23(10):3199–3205PubMedPubMedCentralCrossRef

30.

Kim YJ, Kim K (2016) Radiation therapy for malignant phyllodes tumor of the breast: an analysis of SEER data. Breast 32:26–32PubMedCrossRef

31.

Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, Hunt KK et al (2000) Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89(7):1502–1511PubMedCrossRef

32.

Pandey M, Mathew A, Kattoor J, Abraham EK, Mathew BS, Rajan B et al (2001) Malignant phyllodes tumor. Breast J 7(6):411–416PubMedCrossRef

33.

Soumarova R, Seneklova Z, Horova H, Vojkovska H, Horova I, Budikova M et al (2004) Retrospective analysis of 25 women with malignant cystosarcoma phyllodes-treatment results. Arch Gynecol Obstet 269(4):278–281PubMedCrossRef

34.

Mitus J, Reinfuss M, Mitus JW, Jakubowicz J, Blecharz P, Wysocki WM et al (2014) Malignant phyllodes tumor of the breast: treatment and prognosis. Breast J 20(6):639–644PubMedCrossRef

35.

Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H et al (2012) Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 65(1):69–76PubMedCrossRef

36.

Ben Hassouna J, Damak T, Gamoudi A, Chargui R, Khomsi F, Mahjoub S et al (2006) Phyllodes tumors of the breast: a case series of 106 patients. Am J Surg 192(2):141–147PubMedCrossRef

37.

Kim S, Kim JY, Kim DH, Jung WH, Koo JS (2013) Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat 141(3):353–363PubMedCrossRef

38.

Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL et al (2005) Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 91(3):185–194PubMedCrossRef

39.

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347(16):1233–1241PubMedCrossRef

40.

Kang JK, Kim MS, Jang WI, Seo YS, Kim HJ, Cho CK et al (2016) The clinical utilization of radiation therapy in Korea between 2009 and 2013. Radiat Oncol J 34(2):88–95PubMedPubMedCentralCrossRef

41.

Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E et al (2016) Phyllodes tumours of the breast: a consensus review. Histopathology 68(1):5–21PubMedPubMedCentralCrossRef

42.

Lee JJB, Choi J, Ahn SG, Jeong J, Lee IJ, Park K et al (2017) In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost. Radiat Oncol J 35(2):121–128PubMedPubMedCentralCrossRef

43.

Kim J, Kim JH, Kim OB, Oh YK, Park SG (2017) Clinical significance of the lymph node ratio in N1 breast cancer. Radiat Oncol J 35(3):227–232PubMedPubMedCentralCrossRef

44.

Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW (2007) Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw 5(3):324–330PubMedCrossRef

Titel: Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08)
verfasst von: Noorie Choi
Kyubo Kim
Kyung Hwan Shin
Yumi Kim
Hyeong-Gon Moon
Won Park
Doo Ho Choi
Su Ssan Kim
Seung Do Ahn
Tae Hyun Kim
Mison Chun
Yong Bae Kim
Suzy Kim
Byung Ock Choi
Jin Hee Kim
Publikationsdatum: 28.05.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4838-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08)